Bristol Myers Squibb News

An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells.

A Cancer Research UK initiative to improve cancer gene testing has prompted two pharmaceutical companies to plan pioneering international trials into targeted cancer treatments in the UK.

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 of its investigational anti-PD-1 ... (more)

Overview -- Standard & Poor's Ratings Services has revised its criteria regarding the linkage of issuers' long-term and short-term ratings as they relate to liquidity.

Bristol-Myers Squibb is making progress developing a new drug to assist the body's immune system in its ability to find and attack cancer cells.

U.S. Republican presidential candidate and former Governor of Massachusetts Mitt Romney addresses supporters during his Wisconsin and Maryland primary night rally in Milwaukee, Wisconsin, April 3, 2012.

In addition to Bristol-Myers Squibb, the II-ON is currently comprised of ten leading cancer-research institutions, including: "The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes." .Clinica Universidad Navarra, Pamplona, ... (more)

Bristol-Myers Squibb has formed the International Immuno-Oncology Network , a global collaboration between industry and academia intended to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the body's immune system to fight cancer.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

Lamberto Andreotti , chief executive officer, will answer questions about the company at 9 a.m. EST.

Editor's Note: The following is a news release issued by the Mercer County chapter of the National Alliance on Mental Illness.

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.

A scientist for the French firm Sanofi-Aventis, which made and marketed the blood-thinner with Bristol-Myers Squibb.

Shares of Bristol Myers Squibb opened at 32.75 on Friday. Bristol Myers Squibb has a 52 week low of $25.69 and a 52 week high of $35.44. The company has a market cap of $55.318 billion and a P/E ratio of 14.69. Bristol Myers Squibb last announced its earnings results on Thursday, April 26th.

Editor's Note: The following advisory was issued today by the Lawrence Township Health Department.

Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.'s Plavix after the drug loses U.S. patent protection Thursday.

Jeremy Levin has a big task on his hands. The former Londoner has moved to Israel to become boss of the country's largest company.

Methods Patients who initiated warfarin therapy between Jan 2005 and Jun 2009 and had a healthcare claim related to AF within 30 days prior to the first warfarin claim, but no evidence of valvular disease, were included.

NEW YORK Football fans going to the games this fall can get a program, a foam finger, and a cancer screening.